Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit
- PMID: 23216370
- PMCID: PMC3690100
- DOI: 10.1111/bcp.12034
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit
Abstract
Imagine a medicine that is expected to have very limited effects based upon knowledge of its pharmacology and (patho)physiology and that is studied in the wrong population, with low-quality studies that use a surrogate end-point that relates to the clinical end-point in a partial manner at most. Such a medicine would surely not be recommended. The use of recombinant human erythropoietin (rHuEPO) to enhance performance in cycling is very common. A qualitative systematic review of the available literature was performed to examine the evidence for the ergogenic properties of this drug, which is normally used to treat anaemia in chronic renal failure patients. The results of this literature search show that there is no scientific basis from which to conclude that rHuEPO has performance-enhancing properties in elite cyclists. The reported studies have many shortcomings regarding translation of the results to professional cycling endurance performance. Additionally, the possibly harmful side-effects have not been adequately researched for this population but appear to be worrying, at least. The use of rHuEPO in cycling is rife but scientifically unsupported by evidence, and its use in sports is medical malpractice. What its use would have been, if the involved team physicians had been trained in clinical pharmacology and had investigated this properly, remains a matter of speculation. A single well-controlled trial in athletes in real-life circumstances would give a better indication of the real advantages and risk factors of rHuEPO use, but it would be an oversimplification to suggest that this would eradicate its use.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Figures
) before (
) and after (▴) treatment with rHuEPO in the different studies per treated group (bars representing SD). N is the number of subjects in each group, with an asterisk indicating that the article reported
values only in litres per minute, which has been converted to millilitres per kilogram per minute by dividing this value by mean weight of the group for comparison purposes (no SD is given for these studies because of this conversion). Studies above the horizontal red dotted line were performed using subjects classified as untrained, while below the horizontal line the subjects were classified as trained cyclists. Vertical dashed lines represent minimal values of
for different classifications of cyclists as suggested by Jeukendrup et al. (brown dashed line, trained; red dashed line, well trained; green dashed line, elite; and yellow dashed line, world class).
,
; ▴,
;
, trained;
, well-trained;
, elite; and
, world classComment in
-
World-class cyclists on erythropoietin.Br J Clin Pharmacol. 2014 Mar;77(3):582. doi: 10.1111/bcp.12186. Br J Clin Pharmacol. 2014. PMID: 23772931 Free PMC article. No abstract available.
-
Little soldiers in their cardboard cells.Br J Clin Pharmacol. 2014 Mar;77(3):580-1. doi: 10.1111/bcp.12187. Br J Clin Pharmacol. 2014. PMID: 23772979 Free PMC article. No abstract available.
References
-
- United States Anti-Doping Agency. 2012. Reasoned decision of the united states anti-doping agency on disqualification and ineligibility – united states anti-doping agency, claimant, v. lance armstrong, Respondent.
-
- Sackmann E. Biological membranes architecture and function. In: Lipowsky R, Sackmann E, editors. Handbook of Biological Physics. Amsterdam: Elsevier; 1995. pp. 1–62.
-
- Ratcliffe P, Eckardt K, Bauer C. Hypoxia, erythropoietin gene expression, and erythropoiesis. In: Fregly MJ, Blatteis CM, editors. Handbook of Physiology-Environmental Physiology. New York: Published for the American Physiological Society by Oxford University Press; 1996. pp. 1125–1153.
-
- Carnot P, DeFlandre C. Sur l'activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci (Paris) 1906;143:384–386.
-
- Imai N, Kawamura A, Higuchi M, Oh-Eda M, Orita T, Kawaguchi T, Ochi N. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem. 1990;107:352–359. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
